Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix

Gynecologic Oncology

Volumn 127, Issue 2, 2012, Pages 267-272

  Phippen, Neil T ^a   Leath III, Charles A ^a   Chino, Junzo P ^b   Jewell, Elizabeth L ^c   Havrilesky, Laura J ^b   Barnett, Jason C ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Cervix cancer; Cost effectiveness; Gemcitabine; Quality of life

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; ANOREXIA; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84867397246     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.002     Document Type: Conference Paper

References (23)

1. NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy Plus Radiation Improves Survival 1999 National Cancer Institute [cited 2011 20 July]; Available from: http://www.cancer.gov/newscenter/pressreleases/1999/ cervicalcancer
2. H.M. Keys, B.N. Bundy, F.B. Stehman, L.I. Muderspach, W.E. Chafe, and C.L. Suggs III Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 15 Apr 15 1999 1154 1161
3. M. Morris, P.J. Eifel, J. Lu, P.W. Grigsby, C. Levenback, and R.E. Stevens Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 15 Apr 15 1999 1137 1143
4. W.A. Peters III, P.Y. Liu, R.J. Barrett II, R.J. Stock, B.J. Monk, and J.S. Berek Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 8 Apr 2000 1606 1613
5. P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, and M.A. Maiman Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 15 Apr 15 1999 1144 1153
6. C.W. Whitney, W. Sause, B.N. Bundy, J.H. Malfetano, E.V. Hannigan, and W.C. Fowler Jr. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 5 May 1999 1339 1348
7. A. Duenas-Gonzalez, J.J. Zarba, F. Patel, J.C. Alcedo, S. Beslija, and L. Casanova Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix J Clin Oncol 29 13 May 1 2011 1678 1685
8. J.S.H. Ferlay, F. Bray, D. Forman, C. Mathers, and D.M. Parkin GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] 2010 International Agency for Research on Cancer Lyon, France [cited 2011 20 July]; Available from: http://globocan.iarc.fr
9. A.H. Wallace, L.J. Havrilesky, F.A. Valea, J.C. Barnett, A. Berchuck, and E.R. Myers Projecting the need for gynecologic oncologists for the next 40 years Obstet Gynecol 116 6 Dec 2010 1366 1372
10. I.M. de Kok, J.J. Polder, J.D. Habbema, L.M. Berkers, W.J. Meerding, and M. Rebolj The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening Br J Cancer 100 8 Apr 21 2009 1240 1244
11. A. Trotti, A.D. Colevas, A. Setser, V. Rusch, D. Jaques, and V. Budach CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 3 Jul 2003 176 181
12. Medicare Fee-For-Service Payment. Centers For Medicare and Medicaid Services [cited 2011 10 August]; Available from: https://www.cms.gov
13. S.M. Koroukian, H. Beaird, E. Madigan, and M. Diaz End-of-life expenditures by Ohio Medicaid beneficiaries dying of cancer Health Care Financ Rev 28 2 Winter 2006 65 80
14. Healthcare Cost and Utilization Project 2009 Agency for Healthcare Research and Quality Rockville, MD [cited 2011 4 December]; Available from: http://www.hcupnet.ahrq.gov
15. Consumer Price Index. Bureau of Labor Statistics [cited 2011 10 August]; Available from: http://www.bls.gov/cpi
16. E.L. Jewell, M. Smrtka, G. Broadwater, F. Valea, D.M. Davis, and K.C. Nolte Utility scores and treatment preferences for clinical early-stage cervical cancer Value Health 14 4 Jun 2011 582 586
17. P. Muennig Cost-Effectiveness Analysis in Health 2008 Jossey-Bass San Francisco
18. A.L. Caplan Will evidence ever be sufficient to resolve the challenge of cost containment? J Clin Oncol 29 15 May 20 2011 1946 1948
19. L.X. Clegg, M.E. Reichman, B.A. Miller, B.F. Hankey, G.K. Singh, and Y.D. Lin Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study Cancer Causes Control 20 4 May 2009 417 435
20. G. Thomas Are we making progress in curing advanced cervical cancer? J Clin Oncol 29 13 May 1 2011 1654 1656
21. P.G. Rose, K. Degeest, S. McMeekin, and N. Fusco A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study Gynecol Oncol 107 2 Nov 2007 274 279
22. E.M. Swisher, R.E. Swensen, B. Greer, H. Tamimi, B.A. Goff, and R. Garcia Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium Gynecol Oncol 101 3 Jun 2006 429 435
23. J.L. Forrest, I. Ackerman, L. Barbera, E.A. Barnes, M. Davidson, and A. Kiss Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix Int J Gynecol Cancer 20 6 Aug 2010 1074 1078